566 related articles for article (PubMed ID: 34996736)
21. Growing knowledge of the mTOR signaling network.
Huang K; Fingar DC
Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
[TBL] [Abstract][Full Text] [Related]
22. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
23. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
24. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
[TBL] [Abstract][Full Text] [Related]
26. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
27. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
28. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
29. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting 4EBP1 in Glioblastoma.
Fan QW; Nicolaides TP; Weiss WA
Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243
[TBL] [Abstract][Full Text] [Related]
31. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
32. PI3K/mTOR signaling regulates prostatic branching morphogenesis.
Ghosh S; Lau H; Simons BW; Powell JD; Meyers DJ; De Marzo AM; Berman DM; Lotan TL
Dev Biol; 2011 Dec; 360(2):329-42. PubMed ID: 22015718
[TBL] [Abstract][Full Text] [Related]
33. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.
Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109
[TBL] [Abstract][Full Text] [Related]
34. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.
Melick CH; Jewell JL
Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294
[TBL] [Abstract][Full Text] [Related]
35. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
36. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
37. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
38. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]